BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, January 28, 2026
Home » Authors » Haky Moon

Articles by Haky Moon

New manufacturing deal a win-win for Sun Pharma and Samsung Biologics

July 7, 2017
By Haky Moon
HONG KONG – Facing increased U.S. regulatory scrutiny, India's largest drugmaker, Sun Pharmaceutical Industries Ltd., is outsourcing some of its manufacturing in a deal that provides South Korea's Samsung Biologics Co. Ltd., the biologics manufacturing arm of the Samsung conglomerate, an opportunity to expand its market share.
Read More

U.S. stent makers view India price caps with suspicion

July 6, 2017
By Haky Moon

India's medical device parks projected to reduce product import dependency

June 27, 2017
By Haky Moon

Genexine cleared to initiate second clinical trial of GX-188E

June 21, 2017
By Haky Moon
HONG KONG – The collaboration between Merck & Co. Inc. and South Korean company Genexine Inc. is just a few steps away from tackling human papillomavirus (HPV)-associated cancers, with Genexine receiving the go-ahead from the South Korean Ministry of Food and Drug Safety (MFDS) for a phase Ib/II trial testing a combination vaccine.
Read More

Korea's Orum Therapeutics raises $8M in series A financing

June 21, 2017
By Haky Moon
HONG KONG – South Korean startup Orum Therapeutics Inc. has a shot at effectively blocking RAS gene function with an innovative technology co-developed with Ajou University in South Korea and last week raised $8 million in a series A round to advance work in oncology indications.
Read More

Genexine cleared to initiate second clinical trial of GX-188E

June 21, 2017
By Haky Moon
HONG KONG – The collaboration between Merck & Co. Inc. and South Korean company Genexine Inc. is just a few steps away from tackling human papillomavirus (HPV)-associated cancers, with Genexine receiving the go-ahead from the South Korean Ministry of Food and Drug Safety (MFDS) for a phase Ib/II trial testing a combination vaccine.
Read More

Price controls have India's med-tech industry bracing for negative implications

June 19, 2017
By David Ho and Haky Moon

Korea's Orum Therapeutics raises $8M in series A financing

June 19, 2017
By Haky Moon
HONG KONG – South Korean startup Orum Therapeutics Inc. has a shot at effectively blocking RAS gene function with an innovative technology co-developed with Ajou University in South Korea and last week raised $8 million in a series A round to advance work in oncology indications.
Read More

AI health care boom coming to China as new solutions are desparately needed

June 12, 2017
By Haky Moon

South Korea imports less med-tech products while local production grows

June 8, 2017
By Haky Moon
Previous 1 2 3 4 5 6 7 8 9 … 17 18 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 26, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 27, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Dice spelling out D-E-A-L-?, yes, no

    Muted and missing M&As: JPM deals absent in 2026

    BioWorld
    For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing